| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 144 |
| 05 Nov 2026 |
Form 4: Clase Neera, Chief Commercial Officer
Granted 10,587 Stock Option (right to buy) · Granted 6,678 Restricted Stock Units |
| 05 Nov 2026 |
Form 3: Clase Neera, Chief Commercial Officer
Holds 14,800 shares of Common Stock |
| 05 Nov 2026 | SCHEDULE 13G |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year |
| 13 Oct 2026 | S-3ASR |
| 13 Oct 2026 | S-3ASR |
| 13 Oct 2026 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information combines the historical financial position and results of operations of Tarsus Pharmaceuticals, Inc., a Delaware corporation (“Tarsus”), and Alkeus Pharmaceutical... |
| 17 Sep 2026 |
Form 4: Pyott David E I, Director
Received 201 shares by exercise or conversion |
| 17 Sep 2026 |
Form 4: Yarno Wendy L, Director
Received 302 shares by exercise or conversion |
| 17 Sep 2026 |
Form 4: Link William J Phd, Director
Received 201 shares by exercise or conversion · Sold 12,500 shares ($980K) |
| 15 Sep 2026 | 144 |
| 10 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Other Events
Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMIS... |
| 09 Sep 2026 |
Form 4: Azamian Bobak R., Director
Sold 10,000 shares ($906K) |
| 09 Sep 2026 |
Form 4: Lin Elizabeth Yeu, Chief Medical Officer
Sold 13,953 shares ($1.22M) |
| 09 Sep 2026 |
Form 4: Neervannan Seshadri, Chief Operating Officer
Sold 4,564 shares ($388K) |
| 04 Sep 2026 | 144 |
| 04 Sep 2026 | 144 |
| 04 Sep 2026 | 144 |
Loading...